Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Authors
Keywords
NK/T-cell lymphoma, PD-1 blockade, Pembrolizumab
Journal
Journal of Hematology & Oncology
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-31
DOI
10.1186/s13045-018-0559-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical applications of PD-L1 bioassays for cancer immunotherapy
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
- (2017) Bingshan Liu et al. Journal of Hematology & Oncology
- PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
- (2017) Jun Wang et al. Journal of Hematology & Oncology
- The diagnosis and management of NK/T-cell lymphomas
- (2017) Eric Tse et al. Journal of Hematology & Oncology
- Immunotherapy in hematologic malignancies: past, present, and future
- (2017) Annie Im et al. Journal of Hematology & Oncology
- Checkpoint inhibitors in hematological malignancies
- (2017) Chi Young Ok et al. Journal of Hematology & Oncology
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China
- (2016) X. Li et al. CLINICAL CANCER RESEARCH
- Nivolumab in the Treatment of Hodgkin Lymphoma
- (2016) Stephen M. Ansell CLINICAL CANCER RESEARCH
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic options in peripheral T cell lymphoma
- (2016) Yaping Zhang et al. Journal of Hematology & Oncology
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
- (2016) Xi-wen Bi et al. Journal of Hematology & Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma
- (2014) LIJUAN HAN et al. Oncology Letters
- How I treat NK/T-cell lymphomas
- (2013) E. Tse et al. BLOOD
- Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
- (2013) D Atanackovic et al. LEUKEMIA
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
- (2012) Y.-L. Kwong et al. BLOOD
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
- (2011) Motoko Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia
- (2010) Yok-Lam Kwong INTERNATIONAL JOURNAL OF HEMATOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies
- (2009) Y-L Kwong BONE MARROW TRANSPLANTATION
- Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009
- (2009) Yok-Lam Kwong et al. LANCET ONCOLOGY
- Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study
- (2008) Jeeyun Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
- (2008) Ilyssa O. Gordon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search